← Back to Browse

AxoGen, Inc.

AXGN • Healthcare

78
Grade B
Compass
Current Price
$40.29
Market Cap
$1.5B

About AxoGen, Inc.

AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves;...

Quality Assessment

AxoGen, Inc. is a above-average quality healthcare company with a Compass Score of 78. This stock shows solid fundamentals with room for improvement in some areas. Worth considering for a diversified portfolio.

Score Breakdown

The Compass Score is based on 6 quality factors identified by academic research.

Click any factor to see detailed metrics

Valuation Metrics

Click any metric for details

Technical Overview

Click any metric for details

Wall Street View

Consensus
N/A
Analysts
5
Price Target
๐Ÿ”’
Upside
๐Ÿ”’

Growth Projections

Projected EPS Growth
๐Ÿ”’
Projected Revenue Growth
๐Ÿ”’

Financial Health

Click any metric for details

Important Disclaimer

The Compass Score is for educational purposes only and does not constitute financial advice. Past performance does not guarantee future results. Always do your own research and consider consulting a financial advisor before making investment decisions.